Literature DB >> 23227080

Second Complete Remission of Relapsed Stage IV Non-Small Cell Lung Cancer Following Retreatment.

Su Jin Yoo1, Jeong Eun Lee, Sun Young Jung, Dong Il Park, Myoung Rin Park, Hee Sun Park, Sung Soo Jung, Ju Ock Kim, Sun Young Kim.   

Abstract

Non-small cell lung cancer (NSCLC) is the leading cause of cancer related deaths. Most patients were presented with advanced disease at the time of diagnosis. In advanced NSCLC, it is almost impossible to anticipate complete remission by using only cytotoxic chemotherapy or molecularly targeted agents. In our case, two patients were diagnosed as advanced NSCLC and received chemotherapy. They achieved complete response (CR). After finishing treatment, disease recurred. They were retreated with the same regimens and achieved second CR. Until now, they have received each regimen, continuously, and the CR state has been maintained.

Entities:  

Keywords:  Carcinoma, Non-Small-Cell Lung; Maintenance Chemotherapy; Remission Induction; Retreatment

Year:  2012        PMID: 23227080      PMCID: PMC3510290          DOI: 10.4046/trd.2012.72.4.381

Source DB:  PubMed          Journal:  Tuberc Respir Dis (Seoul)        ISSN: 1738-3536


  3 in total

Review 1.  Retreatment of patients with the same chemotherapy: implications for clinical mechanisms of drug resistance.

Authors:  S Cara; I F Tannock
Journal:  Ann Oncol       Date:  2001-01       Impact factor: 32.976

2.  Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.

Authors:  Federico Cappuzzo; Tudor Ciuleanu; Lilia Stelmakh; Saulius Cicenas; Aleksandra Szczésna; Erzsébet Juhász; Emilio Esteban; Olivier Molinier; Wolfram Brugger; Ivan Melezínek; Gaëlle Klingelschmitt; Barbara Klughammer; Giuseppe Giaccone
Journal:  Lancet Oncol       Date:  2010-05-20       Impact factor: 41.316

3.  Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer.

Authors:  Hiroshi Yokouchi; Koichi Yamazaki; Ichiro Kinoshita; Jun Konishi; Hajime Asahina; Noriaki Sukoh; Masao Harada; Kenji Akie; Shigeaki Ogura; Takashi Ishida; Mitsuru Munakata; Hirotoshi Dosaka-Akita; Hiroshi Isobe; Masaharu Nishimura
Journal:  BMC Cancer       Date:  2007-03-20       Impact factor: 4.430

  3 in total
  1 in total

Review 1.  Drug rechallenge and treatment beyond progression--implications for drug resistance.

Authors:  Elizabeth A Kuczynski; Daniel J Sargent; Axel Grothey; Robert S Kerbel
Journal:  Nat Rev Clin Oncol       Date:  2013-09-03       Impact factor: 66.675

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.